参考文献/References:
[1] Sun H,Saeedi P,Karuranga S,et al. IDF diabetes Atlas: Global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract,2021,183:109119.
[2] Beckman JA,Creager MA. Vascular Complications of Diabetes[J]. Circ Res,2016,118(11):1771-1785.
[3] Maranta F,Cianfanelli L,Cianflone D. Glycaemic control and vascular complications in diabetes mellitus type 2[J]. Adv Exp Med Biol,2021,1307:129-152.
[4] Poznyak A,Grechko AV,Poggio P,et al. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation[J]. Int J Mol Sci,2020,21(5):1835.
[5] Chilelli NC,Cremasco D,Cosma C,et al. Effectiveness of a diet with low advanced glycation end products,in improving glycoxidation and lipid peroxidation: a long-term investigation in patients with chronic renal failure[J]. Endocrine,2016,54(2):552-555.
[6] Ruparelia N,Choudhury R. Inflammation and atherosclerosis: what is on the horizon?[J]. Heart ,2020,106(1):80-85.
[7] Antoniades C,Tousoulis D,Marinou K,et al. Effects of insulin dependence on inflammatory process,thrombotic mechanisms and endothelial function,in patients with type 2 diabetes mellitus and coronary atherosclerosis[J]. Clin Cardiol,2007,30(6):295-300.
[8] Ciccone V,Genah S,Morbidelli L. Endothelium as a source and target of H2S to improve its trophism and function[J]. Antioxidants(Basel),2021,10(3):486.
[9] Chen CS,Pan BY,Tsai PH,et al. Kansuinine A ameliorates atherosclerosis and human aortic endothelial cell apoptosis by inhibiting reactive oxygen species production and suppressing IKKβ/IκBα/NF-κB Signaling[J]. Int J Mol Sci,2021,22(19):10309.
[10] Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis[J]. Acta Med Indones,2007,39(2):86-93.
[11] Yang S,Wang J,Tong L,et al. Research progress in apoptosis of vascular smooth muscle cells in atherosclerosis[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban,2021,46(8):872-876.
[12] Tsai YT,Yeh HY,Chao CT,et al. Superoxide dismutase 2 (SOD2) in vascular calcification: a focus on vascular smooth muscle cells,calcification pathogenesis,and therapeutic strategies[J]. Oxid Med Cell Longev,2021,2021:6675548.
[13] Vorkapic E,Kunath A,Wagsater D. Effects of osteoprotegerin/TNFRSF11B in two models of abdominal aortic aneurysms[J]. Mol Med Rep,2018,18(1):41-48.
[14] Van Campenhout A,Golledge J. Osteoprotegerin,vascular calcification and atherosclerosis[J]. Atherosclerosis,2009,204(2):321-329.
[15] Dutka M,Bobiński R ,Wojakowski W,et al. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases[J]. Heart Fail Rev,2022(4):1395-1411.
[16] Pezhman L,Sheikhzadeh Hesari F,Ghiasi R,et al. The impact of forced swimming on expression of RANKL and OPG in a type 2 diabetes mellitus rat model[J]. Arch Physiol Biochem,2019,125(3):195-200.
[17] Candido R,Toffoli B,Corallini F,et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo[J]. J Vasc Res,2010,47(3):252-261.
[18] Perez de Ciriza C,Moreno M,Restituto P,et al. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification[J]. Clin Biochem,2014,47(18):272-278.
[19] Ma X,Liu Z,Ilyas I,et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential[J]. Int J Biol Sci,2021,17(8):2050-2068.
[20] Ghosh-Swaby OR,Goodman SG,Leiter LA,et al. Glucose-lowering drugs or strategies,atherosclerotic cardiovascular events,and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol,2020,8(5):418-435.
[21] Marso SP,Baeres FMM,Bain SC,et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure[J]. J Am Coll Cardiol,2020,75(10):1128-1141.
[22] Senior PA. Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation[J]. Atherosclerosis,2021,335:16-22.
[23] Karetnikova VN,Belen’kova IuA,Zykov MV,et al. Multifocal atherosclerosis as a factor of unfavorable prognosis in patients with ST elevation myocardial infarction and type 2 diabetes mellitus[J]. Kardiologiia,2013,53(4):12-18.
[24] Strobescu-Ciobanu C,Giu?c? SE ,C?runtu ID,et al. Osteopontin and osteoprotegerin in atherosclerotic plaque—Are they significant markers of plaque vulnerability?[J]. Rom J Morphol Embryol ,2020,61(3):793-801.
[25] Bucay N,Sarosi I,Dunstan CR,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification[J]. Genes Dev,1998,12(9):1260-1268.
[26] Udagawa N,Koide M,Nakamura M,et al. Osteoclast differentiation by RANKL and OPG signaling pathways[J]. J Bone Miner Metab,2021,39(1):19-26.
[27] Chang HJ,Li TF,Guo JL,et al. Effects of high glucose on expression of OPG and RANKL in rat aortic vascular smooth muscle cells[J]. Asian Pac J Trop Med,2015,8(3):209-213.
[28] Toffoli B,Fabris B,Bartelloni G,et al. Dyslipidemia and diabetes increase the OPG/TRAIL ratio in the cardiovascular system[J]. Mediators Inflamm,2016,2016:6529728.
[29] Wallentin L,Eriksson N,Olszowka M,et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: a retrospective study[J]. PLoS Med,2021,18(1):e1003513.
[30] Alves-Lopes R,Neves KB,Strembitska A,et al. Osteoprotegerin regulates vascular function through syndecan-1 and NADPH oxidase-derived reactive oxygen species[J]. Clin Sci (Lond),2021,135(20):2429-2444.
[31] Yan ZP,Li JT,Zeng N,et al. Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy[J]. Cardiol J,2021,28(3):473-482.
[32] Zeng P,Yang J,Liu L,et al. ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway[J]. Theranostics,2021,11(3):1129-1146.
[33] Hankittichai P,Lou HJ,Wikan N,et al. Oxyresveratrol Inhibits IL-1β-induced inflammation via suppressing AKT and ERK1/2 activation in human microglia,HMC3[J]. Int J Mol Sci,2020,21(17):6054.
[34] Shi H,Qin Y,Tian Y,et al. Interleukin-1beta triggers the expansion of circulating granulocytic myeloid-derived suppressor cell subset dependent on Erk1/2 activation[J]. Immunobiology,2021,227(1):152165.
相似文献/References:
[1]张若愚,综述,殷跃辉,等.2型糖尿病及其药物对心房颤动的影响[J].心血管病学进展,2016,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
ZHANG Ruoyu,YIN Yuehui.Effect of Type 2 Diabetes Mellitus and Diabetic Drugs on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
[2]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(8):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[3]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(8):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
[4]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(8):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[5]张明 王敬萍.Nur77和GRP78与糖尿病心肌缺血再灌注损伤的关系研究[J].心血管病学进展,2020,(6):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
ZHANG Ming Wang Jingping.Relationship between Nur77 and GRP78 and Myocardial Ischemia-reperfusion Injury in Diabetic Patients[J].Advances in Cardiovascular Diseases,2020,(8):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
[6]麦尔耶姆·瓦热斯 罗心平 周鹏.糖尿病与心力衰竭：2型糖尿病是心力衰竭的独立危险因素？[J].心血管病学进展,2020,(7):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
Maieryemu·Waresi,LUO Xinping,ZHOU Peng.Diabetes and Heart Failure: Is Type 2 Diabetes an Independent Risk Factor for Heart Failure?[J].Advances in Cardiovascular Diseases,2020,(8):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
[7]廖丽萍 周跟东 张晓红.血清甘油三酯葡萄糖乘积指数与代谢性疾病的研究进展[J].心血管病学进展,2020,(11):1189.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[8]高婧晗 刘飞 杨晓蕾 夏云龙.钙离子稳态的调控在糖尿病相关心房颤动中的作用[J].心血管病学进展,2021,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]
GAO Jinghan,LIU Fei,YANG Xiaolei,et al.Regulation of Calcium Homeostasis in Diabetes-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(8):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]
[9]杨帆 吴建军.五味子乙素通过半胱天冬酶凋亡途径对抗高糖诱导的心肌细胞氧化应激损伤[J].心血管病学进展,2022,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.022]
YANG Fan,WU Jianjun.Sch.B Protects High Glucose-Induced Cardiomyocytes from Oxidative Stress Injury via Caspase Pathway[J].Advances in Cardiovascular Diseases,2022,(8):188.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.022]
[10]邹昕宇 杨帆 吴建军 邢磊.端粒长度在心脑血管疾病的研究进展[J].心血管病学进展,2022,(12):1131.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.017]
ZOU Xinyu,YANG Fan,WU Jianjun,et al.Telomere Length in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(8):1131.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.017]